Healthcare Startup MedGenome Secures $20 Million From Sequoia

Company Name : MedGenome
Funding Amount : $20mn
Investor(s) Sequoia Capital.
Funding Round : Series B

MedGenome ,a provider of genomics research services globally, today announced $20 million Series B investment from Sequoia Capital.

MedGenome’s Series A funding round was led by Emerge Ventures. With the conclusion of Series B funding, Abhay Pandey (Sequoia Capital) will join the Board of Directors joining Sam Santhosh, Mahesh Pratapneni (Emerge Ventures) and Dhiraj Rajaram (Mu Sigma).

The investment will support MedGenome in accelerating the expansion of its portfolio of genetic tests, enhancement of sequencing facilities in India and the US, and expanding its collaborative network with speciality hospitals / clinics and genomic research institutions in India.

MedGenome is a pioneer in introducing advanced genomic technologies in the country – the latest one being the launch of Natera’s PanoramaTM Non-Invasive Prenatal Test (NIPT) this year. MedGenome is the exclusive commercial partner for PanoramaTM in India with a pan-India collection network. The NIPT adds to MedGenome’s current offering of more than 100 genetic tests across multiple disease areas such as cancer, eye and neurological disorders, metabolic disease and other rare cancers.

With a state-of-the art Next Generation Sequencing (NGS) lab in Bangalore, MedGenome offers genomics-based end-to-end diagnostics solutions in India. Its unique clinical and research focus into population-specific variants drive genomics insights into underlying genetic reasons for disease conditions. Its primary expertise in advanced genomics technologies, bioinformatics and big data analytics helps the development of comprehensive gene panels for clinical diagnostics and accurate analysis of genetic data.

Leave a Reply

Sign Up for NextBigWhat Newsletter